Promiscuous inhibition poses two primary implications for medicinal chemistry assaying. The first is the non-specific binding of protein / enzyme targets themselves. The second is the disruption of assay integrity by inhibiting non-target enzymes used for assay readout. As it can be difficult to distinguish between these two, orthogonal assays are sometimes performed to verify a target binding interaction.